Departments of Dermatology and Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Dermatology. 2013;226(2):97-100. doi: 10.1159/000343221. Epub 2013 May 25.
Hidradenitis suppurativa (HS) is an inflammatory, debilitating skin disease of follicular origin, characterized by painful deep-seated, inflamed lesions in mainly the inverse areas of the body. HS is notoriously difficult to treat and especially severe disease is often resistant to therapy. New therapeutic options are therefore highly needed. Elevated levels of IL-1 have been demonstrated in HS lesions. Here we report for the first time on the sequential treatment with anakinra (an IL-1 receptor antagonist) and golimumab (a TNF-α-neutralizing antibody) of a patient with severe HS and with comorbid psoriatic arthritis. Although adalimumab and golimumab were efficacious in improving arthritis complaints, both failed in improving the severe HS of our patient. Eventually the patient underwent radical excision of the inflammatory lesions and fistulas.
化脓性汗腺炎（HS）是一种起源于毛囊的炎症性、使人虚弱的皮肤病，其特征是在身体的主要反向区域出现疼痛的深部、发炎的病变。HS 很难治疗，特别是严重的疾病通常对治疗有抗药性。因此，非常需要新的治疗选择。已经在 HS 病变中证明了 IL-1 水平升高。在这里，我们首次报告了一例患有严重 HS 和并发银屑病关节炎的患者，用阿那白滞素（IL-1 受体拮抗剂）和戈利木单抗（TNF-α 中和抗体）进行序贯治疗的情况。尽管阿达木单抗和戈利木单抗在改善关节炎症状方面都有效，但对我们患者的严重 HS 均无效。最终，患者接受了炎症性病变和瘘管的根治性切除。
